Literature DB >> 22119225

Multimodality functional imaging of spontaneous canine tumors using 64Cu-ATSM and 18FDG PET/CT and dynamic contrast enhanced perfusion CT.

Anders E Hansen1, Annemarie T Kristensen, Ian Law, Fintan J McEvoy, Andreas Kjær, Svend A Engelholm.   

Abstract

PURPOSE: To compare the distribution and uptake of the hypoxia tracer (64)Cu-diacetyl-bis(N(4)-methylthiosemicarbazone) ((64)Cu-ATSM) PET/CT, FDG PET/CT and dynamic contrast enhanced perfusion CT (DCE-pCT) in spontaneous canine tumors. In addition (64)Cu-ATSM distribution over time was evaluated. METHODS AND MATERIALS: Nine spontaneous cancer-bearing dogs were prospectively enrolled. FDG (1h pi.) and (64)Cu-ATSM (3 and 24h pi.) PET/CT were performed over three consecutive days. DCE-pCT was performed on day 2. Tumor uptake of FDG and (64)Cu-ATSM was assessed semi-quantitatively and the distribution of FDG, (64)Cu-ATSM and CT perfusion parameters correlated.
RESULTS: (64)Cu-ATSM distribution on scans performed 24h apart displayed moderate to strong correlation; however, temporal changes were observed. The spatial distribution pattern of (64)Cu-ATSM between scans was moderately to strongly positively correlated to FDG, whereas the correlation of CT perfusion parameters to FDG and to (64)Cu-ATSM yielded more varying results.
CONCLUSIONS: (64)Cu-ATSM uptake was positively correlated to FDG. (64)Cu-ATSM was found to be relatively stable between PET scans performed at different time points, important temporal changes were however observed in hypo-perfused regions. These findings potentially indicate that prolonged uptake periods for (64)Cu-ATSM imaging may be needed. Although a moderate to strong correlation between (64)Cu-ATSM and FDG PET/CT is observed, the two tracers provide different biological information with an overlapping spatial distribution.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22119225     DOI: 10.1016/j.radonc.2011.10.021

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  16 in total

Review 1.  Defining the Value of a Comparative Approach to Cancer Drug Development.

Authors:  Amy K LeBlanc; Christina N Mazcko; Chand Khanna
Journal:  Clin Cancer Res       Date:  2015-12-28       Impact factor: 12.531

2.  Simultaneous hyperpolarized (13)C-pyruvate MRI and (18)F-FDG-PET in cancer (hyperPET): feasibility of a new imaging concept using a clinical PET/MRI scanner.

Authors:  Henrik Gutte; Adam E Hansen; Sarah T Henriksen; Helle H Johannesen; Jan Ardenkjaer-Larsen; Alexandre Vignaud; Anders E Hansen; Betina Børresen; Thomas L Klausen; Anne-Mette N Wittekind; Nic Gillings; Annemarie T Kristensen; Andreas Clemmensen; Liselotte Højgaard; Andreas Kjær
Journal:  Am J Nucl Med Mol Imaging       Date:  2014-12-15

3.  Spatially resolved regression analysis of pre-treatment FDG, FLT and Cu-ATSM PET from post-treatment FDG PET: an exploratory study.

Authors:  Stephen R Bowen; Richard J Chappell; Søren M Bentzen; Michael A Deveau; Lisa J Forrest; Robert Jeraj
Journal:  Radiother Oncol       Date:  2012-06-08       Impact factor: 6.280

Review 4.  Evaluation of hypoxia with copper-labeled diacetyl-bis(N-methylthiosemicarbazone).

Authors:  Suzanne E Lapi; Jason S Lewis; Farrokh Dehdashti
Journal:  Semin Nucl Med       Date:  2015-03       Impact factor: 4.446

5.  Heterogeneity in intratumor correlations of 18F-FDG, 18F-FLT, and 61Cu-ATSM PET in canine sinonasal tumors.

Authors:  Tyler J Bradshaw; Stephen R Bowen; Ngoneh Jallow; Lisa J Forrest; Robert Jeraj
Journal:  J Nucl Med       Date:  2013-09-16       Impact factor: 10.057

6.  Characterization of tumor heterogeneity using dynamic contrast enhanced CT and FDG-PET in non-small cell lung cancer.

Authors:  P Veit-Haibach; D De Ruysscher; W van Elmpt; M Das; Martin Hüllner; H Sharifi; K Zegers; B Reymen; P Lambin; J E Wildberger; E G C Troost
Journal:  Radiother Oncol       Date:  2013-09-14       Impact factor: 6.280

7.  PET/MRI in cancer patients: first experiences and vision from Copenhagen.

Authors:  Andreas Kjær; Annika Loft; Ian Law; Anne Kiil Berthelsen; Lise Borgwardt; Johan Löfgren; Camilla Bardram Johnbeck; Adam Espe Hansen; Sune Keller; Søren Holm; Liselotte Højgaard
Journal:  MAGMA       Date:  2012-12-25       Impact factor: 2.310

8.  (64)Cu-ATSM and (18)FDG PET uptake and (64)Cu-ATSM autoradiography in spontaneous canine tumors: comparison with pimonidazole hypoxia immunohistochemistry.

Authors:  Anders E Hansen; Annemarie T Kristensen; Jesper T Jørgensen; Fintan J McEvoy; Morten Busk; Albert J van der Kogel; Johan Bussink; Svend A Engelholm; Andreas Kjær
Journal:  Radiat Oncol       Date:  2012-06-15       Impact factor: 3.481

9.  Can DCE-MRI explain the heterogeneity in radiopeptide uptake imaged by SPECT in a pancreatic neuroendocrine tumor model?

Authors:  Karin Bol; Joost C Haeck; Harald C Groen; Wiro J Niessen; Monique R Bernsen; Marion de Jong; Jifke F Veenland
Journal:  PLoS One       Date:  2013-10-08       Impact factor: 3.240

10.  Comparative Oncology: Evaluation of 2-Deoxy-2-[18F]fluoro-D-glucose (FDG) Positron Emission Tomography/Computed Tomography (PET/CT) for the Staging of Dogs with Malignant Tumors.

Authors:  Stefanie M F Seiler; Christine Baumgartner; Johannes Hirschberger; Ambros J Beer; Andreas Brühschwein; Nina Kreutzmann; Silja Laberke; Melanie C Wergin; Andrea Meyer-Lindenberg; Johanna Brandl; Anne-Kathrin von Thaden; Eliane Farrell; Markus Schwaiger
Journal:  PLoS One       Date:  2015-06-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.